| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KCTD11 |
| Uniprot No | Q693B1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-232aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MLGAMFRAGT PMPPNLNSQG GGHYFIDRDG KAFRHILNFL RLGRLDLPRG YGETALLRAE ADFYQIRPLL DALRELEASQ GTPAPTAALL HADVDVSPRL VHFSARRGPH HYELSSVQVD TFRANLFCTD SECLGALRAR FGVASGDRAE GSPHFHLEWA PRPVELPEVE YGRLGLQPLW TGGPGERREV VGTPSFLEEV LRVALEHGFR LDSVFPDPED LLNSRSLRFV RH |
| 预测分子量 | 28 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"KCTD11 inhibits growth and metastasis of neuroblastoma by regulating the Hedgehog pathway"**
- **作者**: Di Marcotullio, L. et al.
- **摘要**: 研究揭示了KCTD11重组蛋白通过结合Gli转录因子抑制Hedgehog信号通路，从而抑制神经母细胞瘤细胞的增殖和转移，为靶向治疗提供了潜在策略。
2. **"Structural and functional analysis of KCTD11-Cullin3 interaction in ubiquitination"**
- **作者**: Canettieri, G. et al.
- **摘要**: 通过重组KCTD11蛋白的生化实验，证实其作为Cullin3泛素连接酶复合体的底物识别亚基，参与调控靶蛋白的泛素化降解，影响细胞周期进程。
3. **"KCTD11 promotes neuronal differentiation by modulating E-protein activity"**
- **作者**: Zarelli, V.E. et al.
- **摘要**: 研究利用重组KCTD11蛋白发现其通过抑制E蛋白(如E47)的转录活性，促进神经干细胞向神经元分化，揭示了其在神经发育中的关键作用。
4. **"KCTD11 as a biomarker in medulloblastoma: Recombinant protein-based analysis"**
- **作者**: Schiavinato, A. et al.
- **摘要**: 通过重组KCTD11蛋白的功能实验，证明其在髓母细胞瘤中低表达与患者不良预后相关，并验证其通过抑制Shh信号通路发挥抑癌功能。
KCTD11 (Potassium Channel Tetramerization Domain-Containing 11), also known as REN, is a member of the KCTD protein family characterized by a conserved N-terminal BTB/POZ domain. It functions as a substrate-specific adaptor for Cullin3-based E3 ubiquitin ligase complexes, playing a critical role in regulating protein ubiquitination and degradation. KCTD11 is implicated in key cellular processes, including cell proliferation, differentiation, and apoptosis, by targeting proteins like HDAC1 and Gli transcription factors for proteasomal degradation. Its tumor-suppressive activity is well-documented, particularly in neural and glial cancers, where it inhibits Hedgehog signaling and oncogenic pathways.
Recombinant KCTD11 protein is engineered using expression systems (e.g., E. coli or mammalian cells) to produce purified, functionally active forms of the protein for research. This recombinant tool enables mechanistic studies of its interactions with binding partners, ubiquitination substrates, and signaling pathways. Researchers utilize it to explore its role in cancer biology, neurodevelopment, and epigenetic regulation. Additionally, it serves as a reagent for drug discovery efforts aiming to modulate KCTD11-related pathways in diseases linked to its dysregulation, such as glioblastoma or neurodevelopmental disorders. The protein’s structure-function relationships, post-translational modifications, and therapeutic potential remain active areas of investigation.
×
